Austria's Regulatory Chief Secures Top EMA Job
Dr. Christa Wirthumer-Hoche has been elected as the new chair of the Management Board of the European Medicines Agency (EMA).
Dr. Christa Wirthumer-Hoche has been elected as the new chair of the Management Board of the European Medicines Agency (EMA). The post is for a three-year period, and she succeeds Kent Woods, who stepped down as chair of the Board in December.
Wirthumer-Hoche has been head of the Austrian Medicines and Medical Devices Agency since October 2013, and has served as vice-chair of EMA’s Management Board since March 2015. She is also co-chair of the EU Network Training Center that was launched in January 2015 and has served as chair of EMA’s Active Substance Master File Working Group.
“As chair, my ambition is to ensure a strong partnership between EMA, the European Union national competent authorities and the European Commission to guarantee that EMA is able to fulfil its important role of safeguarding human and animal health in Europe,” said Wirthumer-Hoche, who holds a doctorate from the Technical University of Vienna and a diploma in chemistry and biochemistry.
The Management Board sets the EMA’s budget, approves the annual work program, and is responsible for ensuring that the agency works effectively and co-operates successfully with partner organizations across the EU and beyond.
In her statement dated October 19, 2015, Wirthumer-Hoche declared no conflicts of interest. Her replacement as the vice-chair has not been announced yet.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
